Cargando…
Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055015/ https://www.ncbi.nlm.nih.gov/pubmed/30046297 http://dx.doi.org/10.3389/fimmu.2018.01641 |
| _version_ | 1783341101204111360 |
|---|---|
| author | Ozkaynak, M. Fevzi Gilman, Andrew L. London, Wendy B. Naranjo, Arlene Diccianni, Mitchell B. Tenney, Sheena C. Smith, Malcolm Messer, Karen S. Seeger, Robert Reynolds, C. Patrick Smith, L. Mary Shulkin, Barry L. Parisi, Marguerite Maris, John M. Park, Julie R. Sondel, Paul M. Yu, Alice L. |
| author_facet | Ozkaynak, M. Fevzi Gilman, Andrew L. London, Wendy B. Naranjo, Arlene Diccianni, Mitchell B. Tenney, Sheena C. Smith, Malcolm Messer, Karen S. Seeger, Robert Reynolds, C. Patrick Smith, L. Mary Shulkin, Barry L. Parisi, Marguerite Maris, John M. Park, Julie R. Sondel, Paul M. Yu, Alice L. |
| author_sort | Ozkaynak, M. Fevzi |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-6055015 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2018 |
| publisher | Frontiers Media S.A. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-60550152018-07-25 Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931 Ozkaynak, M. Fevzi Gilman, Andrew L. London, Wendy B. Naranjo, Arlene Diccianni, Mitchell B. Tenney, Sheena C. Smith, Malcolm Messer, Karen S. Seeger, Robert Reynolds, C. Patrick Smith, L. Mary Shulkin, Barry L. Parisi, Marguerite Maris, John M. Park, Julie R. Sondel, Paul M. Yu, Alice L. Front Immunol Immunology Frontiers Media S.A. 2018-07-16 /pmc/articles/PMC6055015/ /pubmed/30046297 http://dx.doi.org/10.3389/fimmu.2018.01641 Text en Copyright © 2018 Ozkaynak, Gilman, London, Naranjo, Diccianni, Tenney, Smith, Messer, Seeger, Reynolds, Smith, Shulkin, Parisi, Maris, Park, Sondel and Yu. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| spellingShingle | Immunology Ozkaynak, M. Fevzi Gilman, Andrew L. London, Wendy B. Naranjo, Arlene Diccianni, Mitchell B. Tenney, Sheena C. Smith, Malcolm Messer, Karen S. Seeger, Robert Reynolds, C. Patrick Smith, L. Mary Shulkin, Barry L. Parisi, Marguerite Maris, John M. Park, Julie R. Sondel, Paul M. Yu, Alice L. Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931 |
| title | Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931 |
| title_full | Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931 |
| title_fullStr | Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931 |
| title_full_unstemmed | Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931 |
| title_short | Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931 |
| title_sort | corrigendum: a comprehensive safety trial of chimeric antibody 14.18 with gm-csf, il-2, and isotretinoin in high-risk neuroblastoma patients following myeloablative therapy: children’s oncology group study anbl0931 |
| topic | Immunology |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6055015/ https://www.ncbi.nlm.nih.gov/pubmed/30046297 http://dx.doi.org/10.3389/fimmu.2018.01641 |
| work_keys_str_mv | AT ozkaynakmfevzi corrigendumacomprehensivesafetytrialofchimericantibody1418withgmcsfil2andisotretinoininhighriskneuroblastomapatientsfollowingmyeloablativetherapychildrensoncologygroupstudyanbl0931 AT gilmanandrewl corrigendumacomprehensivesafetytrialofchimericantibody1418withgmcsfil2andisotretinoininhighriskneuroblastomapatientsfollowingmyeloablativetherapychildrensoncologygroupstudyanbl0931 AT londonwendyb corrigendumacomprehensivesafetytrialofchimericantibody1418withgmcsfil2andisotretinoininhighriskneuroblastomapatientsfollowingmyeloablativetherapychildrensoncologygroupstudyanbl0931 AT naranjoarlene corrigendumacomprehensivesafetytrialofchimericantibody1418withgmcsfil2andisotretinoininhighriskneuroblastomapatientsfollowingmyeloablativetherapychildrensoncologygroupstudyanbl0931 AT dicciannimitchellb corrigendumacomprehensivesafetytrialofchimericantibody1418withgmcsfil2andisotretinoininhighriskneuroblastomapatientsfollowingmyeloablativetherapychildrensoncologygroupstudyanbl0931 AT tenneysheenac corrigendumacomprehensivesafetytrialofchimericantibody1418withgmcsfil2andisotretinoininhighriskneuroblastomapatientsfollowingmyeloablativetherapychildrensoncologygroupstudyanbl0931 AT smithmalcolm corrigendumacomprehensivesafetytrialofchimericantibody1418withgmcsfil2andisotretinoininhighriskneuroblastomapatientsfollowingmyeloablativetherapychildrensoncologygroupstudyanbl0931 AT messerkarens corrigendumacomprehensivesafetytrialofchimericantibody1418withgmcsfil2andisotretinoininhighriskneuroblastomapatientsfollowingmyeloablativetherapychildrensoncologygroupstudyanbl0931 AT seegerrobert corrigendumacomprehensivesafetytrialofchimericantibody1418withgmcsfil2andisotretinoininhighriskneuroblastomapatientsfollowingmyeloablativetherapychildrensoncologygroupstudyanbl0931 AT reynoldscpatrick corrigendumacomprehensivesafetytrialofchimericantibody1418withgmcsfil2andisotretinoininhighriskneuroblastomapatientsfollowingmyeloablativetherapychildrensoncologygroupstudyanbl0931 AT smithlmary corrigendumacomprehensivesafetytrialofchimericantibody1418withgmcsfil2andisotretinoininhighriskneuroblastomapatientsfollowingmyeloablativetherapychildrensoncologygroupstudyanbl0931 AT shulkinbarryl corrigendumacomprehensivesafetytrialofchimericantibody1418withgmcsfil2andisotretinoininhighriskneuroblastomapatientsfollowingmyeloablativetherapychildrensoncologygroupstudyanbl0931 AT parisimarguerite corrigendumacomprehensivesafetytrialofchimericantibody1418withgmcsfil2andisotretinoininhighriskneuroblastomapatientsfollowingmyeloablativetherapychildrensoncologygroupstudyanbl0931 AT marisjohnm corrigendumacomprehensivesafetytrialofchimericantibody1418withgmcsfil2andisotretinoininhighriskneuroblastomapatientsfollowingmyeloablativetherapychildrensoncologygroupstudyanbl0931 AT parkjulier corrigendumacomprehensivesafetytrialofchimericantibody1418withgmcsfil2andisotretinoininhighriskneuroblastomapatientsfollowingmyeloablativetherapychildrensoncologygroupstudyanbl0931 AT sondelpaulm corrigendumacomprehensivesafetytrialofchimericantibody1418withgmcsfil2andisotretinoininhighriskneuroblastomapatientsfollowingmyeloablativetherapychildrensoncologygroupstudyanbl0931 AT yualicel corrigendumacomprehensivesafetytrialofchimericantibody1418withgmcsfil2andisotretinoininhighriskneuroblastomapatientsfollowingmyeloablativetherapychildrensoncologygroupstudyanbl0931 |